Fubotv earnings beat by $0.10, revenue topped estimates
The Irrevocable Larson Family Investment Trust has recently increased its stake in Rockwell Medical , Inc. (NASDAQ:RMTI) by purchasing a significant number of shares. According to a recent SEC filing, the trust acquired a total of 90,000 shares of Rockwell Medical’s common stock over the course of April 10 and April 11, 2025. The company, currently valued at $35 million in market capitalization, has shown strong financial health metrics according to InvestingPro data.
The transactions, which amounted to a total value of $94,017, were executed at prices ranging from $1.04 to $1.1009 per share. These acquisitions have raised the trust’s total ownership to 3,557,500 shares, reflecting its continued confidence in the company. According to InvestingPro analysis, the stock appears fairly valued, with analysts setting price targets between $3 and $5.
Rockwell Medical, based in Wixom, Michigan, focuses on the development and commercialization of products for the treatment of iron deficiency and other diseases. The trust’s purchases were made with direct ownership, signaling a strategic move to bolster its investment in the pharmaceutical preparations sector. The company maintains a healthy balance sheet with a current ratio of 2.63 and holds more cash than debt, while analysts expect it to achieve profitability this year.
In other recent news, Rockwell Medical reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share of $0.04 against a forecast of $0. The company also achieved a 21% increase in full-year net sales, reaching $101.5 million. Despite these positive results, Rockwell Medical anticipates a challenging 2025 due to the loss of its largest customer, which is expected to impact revenue by approximately $34 million. The company’s revenue guidance for 2025 is between $65-70 million, a significant decrease from previous estimates. Analysts at H.C. Wainwright responded by lowering their price target for Rockwell Medical to $3.00 from $7.00, while maintaining a Buy rating on the stock. The company is actively engaged in discussions with the departing customer for potential contract extensions or future commitments. Rockwell Medical continues to focus on expanding into international markets and launching new products to mitigate the impact of the customer transition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.